Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from COSMO Pharmaceuticals N.V. ( (CH:COPN) ) is now available.
Cosmo Pharmaceuticals N.V. has achieved significant milestones in its sustainability efforts, receiving an improved ESG rating from S&P Global and an EcoVadis bronze medal for its Italian production site. The company’s S&P Global Corporate Sustainability Assessment rating increased to the 67th percentile, highlighting its success in integrating sustainability into governance, environmental, and social impact areas. Additionally, Cosmo’s partnership with EcoVadis aims to enhance supply chain transparency and risk management, reflecting its commitment to responsible sourcing and continuous improvement in sustainability practices.
The most recent analyst rating on (CH:COPN) stock is a Hold with a CHF67.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a life sciences company specializing in MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company is dedicated to designing, developing, and manufacturing advanced solutions that address critical medical needs, thereby improving the standard of care. Founded in 1997 and headquartered in Dublin, Ireland, Cosmo operates globally, with offices in the USA and Italy, and collaborates with leading pharma and MedTech companies to empower patients and healthcare providers through innovative science and technology.
Average Trading Volume: 19,117
Technical Sentiment Signal: Hold
Current Market Cap: CHF1.05B
For an in-depth examination of COPN stock, go to TipRanks’ Overview page.